Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Summary of Significant Expense Categories and Consolidated Net Loss

The following is a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):

	Three Months Ended March 31,
	2025			2024
Revenue:	$	10,460		$	21,639
Operating costs and expenses:
Cost of goods sold		—			8,534
Clinical development, contract manufacturing and other third party costs
Rezpegaldesleukin (cytokine Treg stimulant)		13,803			8,884
NKTR-255 (IL-15 receptor agonist)		1,389			3,486
NKTR-0165 (tumor necrosis factor receptor type II agonist)		2,281			2,018
Discovery research and other programs		469			1,067
Total clinical development, contract manufacturing and other third party costs		17,942			15,455
Employee costs (a)(b)		11,974			10,317
Facilities costs (a)		3,358			4,532
Other operating costs (a)(c)		17,260			11,205
Other segment expenses		4,461			7,023
Total operating costs and expenses		54,995			57,066
Loss from operations		(44,535	)		(35,427	)
Non-operating income (expense):
Non-cash interest expense on liability related to sale of future royalties		(4,974	)		(5,531	)
Interest income		2,874			4,220
Other income (expense), net		266			(99	)
Total non-operating income (expense), net		(1,834	)		(1,410	)
Loss before provision (benefit) for income taxes and equity method investment		(46,369	)		(36,837	)
Provision (benefit) for income taxes		52			(35	)
Loss before equity method investment		(46,421	)		(36,802	)
Loss from equity method investment		(4,461	)		—
Net loss	$	(50,882	)	$	(36,802	)

Schedule of Other Segment Expense Items Included within Net Loss

Other segment expense items included within net loss include the following (in thousands):

	Three Months Ended March 31,
	2025		2024
Contract termination costs	$	169	$	975
Stock-based compensation (a)		3,898		5,367
Depreciation and amortization expense (a)		394		681
Total other segment expenses	$	4,461	$	7,023

a)Employee costs, facilities costs, other operating costs, stock-based compensation expense and depreciation and amortization expense include amounts reported in research and development expense and general and administrative expense in our Condensed Consolidated Statements of Operations. Such amounts reported in cost of goods sold in our Condensed Consolidated Statements of Operations are included in cost of goods sold in the summary of significant segment expenses.

b)Includes compensation and benefits for our employees and costs for our contractors and temporary workers.

c)Includes legal and patent expenses, information technology infrastructure and other costs, professional accounting, insurance, travel and entertainment and other third-party services and expenses.